Tesamorelin

Tesamorelin (TH9507) is a synthetic 44-amino-acid GHRH analogue matching native GHRH(1-44) with a trans-3-hexenoic acid group esterified to the N-terminal tyrosine. That modification blocks DPP-4 cleavage, the enzyme responsible for native GHRH's roughly two-minute plasma survival.

Developed by Theratechnologies, Inc. of Canada and approved in 2010 as Egrifta for excess abdominal adiposity in HIV-associated lipodystrophy; Egrifta WR (2024) permits weekly rather than daily reconstitution. Off-label use is for body recomposition and anti-ageing, and it remains the only GHRH analogue with that approval.

The "visceral fat peptide" label is a measurement artefact rather than a pharmacological distinction. Tesamorelin shares pathway, receptor and downstream cascade with CJC-1295 and Sermorelin; the difference is that its registration programme used 26-week CT-quantified visceral adipose tissue as the endpoint. Had CJC-1295 been funded through an equivalent trial, comparable data would be expected — no head-to-head study exists.

It is non-androgenic with no effect on testosterone. It is the costliest GH-axis peptide available, requires a prescription in pharmaceutical form, and is prohibited by WADA under Peptide Hormones, Growth Factors and Related Substances.

Formulation behaviour is the defining practical constraint. The hydrophobic N-terminal modification and the sequence's hydrophobic residue load drive intermolecular association at low temperature, producing gelling. The FDA-approved product includes 145 mg of hydroxypropyl betadex as a stabiliser that sequesters those hydrophobic regions; research-grade material is the same molecule but typically lacks it, so stability windows differ while the room-temperature requirement still applies.

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, mimicking hypothalamic GHRH and driving release of endogenous hGH. Negative feedback is preserved, including somatostatin-mediated braking, so pulsatility and regulatory control are retained rather than overridden as they are by exogenous GH.

The axis has two afferent arms. GHRH drives somatotroph output; ghrelin acting at GHS-R1a amplifies it and suppresses somatostatin tone. Simultaneous activation produces a substantially larger pulse than either alone, which is the physiological basis of the nocturnal fasted pulse and the rationale for pairing a GHRH analogue with a GHRP such as ipamorelin. Tesamorelin activates only the GHRH arm.

Downstream, hepatic conversion of GH to IGF-1 carries most of the effect: lipolysis, muscle protein synthesis, recovery, collagen turnover, bone density maintenance. That conversion is insulin-dependent, creating the well-recognised paradox — GH secretion is maximal in the low-insulin, high-ghrelin fasted state, while hepatic IGF-1 generation requires insulin. Physiological timing resolves it: a fasted nocturnal pulse, GH circulating for a few hours, then post-prandial insulin driving conversion the following morning.

Pharmacokinetics: rapid subcutaneous absorption with Cmax at approximately 30 minutes to one hour and a half-life of roughly 26 minutes. The pituitary response outlasts exposure, generating a 2 to 3 hour GH burst. IGF-1 rises gradually and stabilises over 2 to 4 weeks of consistent daily dosing. In the pivotal trial IGF-1 rose 81 percent into the mid-normal range. The short half-life mandates daily administration to sustain axis elevation.

Adipose: reduction of subcutaneous adipose tissue with a marked effect on visceral adipose tissue around liver, stomach and intestines — approximately 15 to 20 percent over 26 weeks, and 27.71 cm squared with a 1.18 kg trunk fat reduction in the 2026 meta-analysis. Loss is preferential in abdomen and upper back. The mechanism is IGF-1-driven lipolysis, not a visceral-specific receptor.

Body composition and metabolism: lean mass preserved and increased by 1.42 kg in pooled data; increased metabolic rate and energy output; triglycerides down approximately 50 mg/dL and total cholesterol to HDL ratio significantly improved in the 412-patient trial.

Hepatic: hepatic fat fraction reduced approximately 37 percent relative to baseline; 35 percent of treated participants fell below the 5 percent NAFLD threshold versus 4 percent on placebo, with significantly less fibrosis progression (10 percent versus 37 percent).

Neurological: supports nerve regeneration after injury and raises neurotransmitters associated with cognitive performance, the basis for its use in neuroregeneration stacks. Ellis et al. (2025) found only a non-significant trend in neurocognitive performance across 73 participants, with no correlation between IGF-1 rise and cognitive change.

Glycaemic: GH is counter-regulatory to insulin. A transient fasting glucose rise was observed at 2 weeks in one study and normalised by 6 months, and Badran et al. (2026) reported no perturbation of glucose metabolism; the pivotal trial found glucose tolerance not worsened. Caution nonetheless applies in insulin resistance and prediabetes, and in diabetics co-administering tirzepatide, where opposing glycaemic effects can degrade control.

Non-androgenic, with no effect on testosterone.

Weeks 1 to 4: users report improved sleep quality in some but not all cases; the GH signal is being established.

Weeks 4 to 6: training recovery improves as IGF-1 stabilises — subjective effect precedes visible change.

Weeks 8 to 12: visible body composition change, conditional on diet and training.

Weeks 12 to 26: the largest visceral fat reductions, matching the 26-week trial window and the 12-month safety extension figure of approximately 18 percent.

A minimum of 3 to 6 months of consistent daily use is required for maximum benefit. Trial discontinuation produced fat reaccumulation over time, which reframes the compound as an accelerator of an existing training, nutrition and sleep base rather than a standalone intervention.

User-reported outcomes: consistent reductions in abdominal circumference over 3 to 6 months, most reliably at the full 2 mg daily protocol; lower doses and inconsistent schedules correlate with slower, weaker results. Improved muscle tone and leaner appearance alongside fat loss are commonly described. Sleep improvement within 2 to 4 weeks and faster inter-session recovery once IGF-1 plateaus are the other recurring themes.

Tolerability profile in practice is dominated by injection site reactions — erythema, pruritus and flushing lasting 10 to 20 minutes post-injection — markedly more frequent and more intense than with CJC-1295 or ipamorelin, while the tachycardia and head rush associated with CJC-1295 are reported less often.

Evidence limitation worth holding in mind: every major trial was conducted in HIV-positive populations with lipodystrophy or NAFLD. No large randomised controlled trials exist in otherwise healthy adults using tesamorelin for body composition or anti-ageing. The mechanism supports the application; the direct clinical evidence does not exist.

Cost is a real constraint: 2 mg daily exhausts a 5 mg vial in 2.5 days, roughly 12 vials per month.

Standard dosing is 2 mg (2000 mcg) subcutaneously once daily, taken from the FDA-approved prescribing information and used across all published trials. No dose-finding studies support sub-2 mg dosing for visceral fat reduction, so dose reduction for cost purposes is unsupported.

Timing is fasted: 30 to 60 minutes pre-bed, or fasted in the morning at least 2 hours before eating. The pre-bed window exploits low insulin and high ghrelin for maximal pulse amplitude; GH circulates 2 to 3 hours overnight driving lipolysis, and post-prandial insulin the next morning supports hepatic IGF-1 conversion. Sleep disruption is a recognised reason to move to morning dosing without loss of efficacy.

Reconstitution: 5 mg vial with 1 mL bacteriostatic water yields 5000 mcg/mL; 2 mg equals 40 units on an insulin syringe, giving 2.5 days per vial. A 0.6% acetic acid stage prior to the bacteriostatic water is used by some to suppress gelling.

Storage diverges from every other peptide. Lyophilised vials: 2 to 8°C refrigerated, or -20°C for extended periods, protected from light. Reconstituted: room temperature, 20 to 25°C, never refrigerated and never frozen, used within 7 days, discarded if cloudy, thickened or gel-like. Cold-induced hydrophobic association is intrinsic to the sequence and present in every vial regardless of manufacturer. Because the failure mode is physical aggregation rather than chemical degradation, a standard COA purity assay will not detect it — dynamic light scattering or size exclusion chromatography would be needed. Apparent success with refrigerated vials generally reflects finishing them before aggregation becomes visible.

Administration: subcutaneous, typically abdomen below the navel, rotating sites, avoiding scarred, bruised or irritated tissue.

Cycling: 26 weeks continuous daily dosing in trials; common off-label practice is 3 to 6 months on with 1 to 2 months off. No evidence establishes that cycling is necessary. Combined protocol: tesamorelin 1 to 2 mg with ipamorelin 100 to 200 mcg, pinned together pre-bed fasted, daily for 60 to 90 days — co-administration in the same window is essential, since splitting them yields two smaller pulses.

The evidence base is substantial but confined almost entirely to HIV-associated lipodystrophy and NAFLD populations.

Falutz et al. (2007/2010) — multicentre, randomised, double-blind, placebo-controlled trial in 412 HIV-infected patients with abdominal fat accumulation, 2 mg tesamorelin or placebo subcutaneously daily for 26 weeks. Visceral adipose tissue fell 15.2 percent versus a 5.0 percent increase on placebo; triglycerides fell 50 mg/dL; total cholesterol to HDL ratio improved significantly; IGF-1 rose 81 percent into the mid-normal range; lean body mass was preserved; glucose tolerance was not worsened. The 12-month safety extension showed approximately 18 percent visceral fat reduction in continued users. Published in the New England Journal of Medicine (2007) and the Journal of Acquired Immune Deficiency Syndromes (2010).

Stanley et al. (2014), JAMA, n=50: net treatment effect of -16.6 percent on visceral adipose tissue and a net -2.9 percent reduction in hepatic lipid to water ratio.

Stanley et al. (2019), Lancet HIV, randomised double-blind multicentre trial, n=61 with HIV and NAFLD: hepatic fat fraction reduced 37 percent relative to baseline; 35 percent fell below the 5 percent NAFLD threshold versus 4 percent on placebo; fibrosis progression 10 percent versus 37 percent.

Badran et al. (2026), Obesity Research and Clinical Practice, meta-analysis of five RCTs: VAT -27.71 cm squared, trunk fat -1.18 kg, lean body mass +1.42 kg, hepatic fat -4.28 percent, no serious adverse effects and no perturbation of glucose metabolism.

Ellis et al. (2025), Journal of Infectious Diseases, Phase 2 randomised open-label trial, n=73: significant waist circumference reduction, but neurocognitive benefit did not differ significantly between groups and IGF-1 rise showed no correlation with cognitive change.

Critical limitation: no large RCTs exist in otherwise healthy adults for general body composition or anti-ageing. Mechanism supports the application; direct clinical evidence in healthy populations does not exist.